According to a report by "The Print" on September 26, India's new generation surgical robot is caught in a "Made in China" controversy. On September 24, SS Innovations (SSI), the local manufacturer of India's first surgical robot, wrote to the Central Drugs Standard Control Organization (CDSCO) of India, accusing another medical device company Merai Newage (MN) of launching a new generation of surgical robots called Mizzo Endo 4000 as a "completely imported rebranded product from China". The Mizzo Endo 4000 is MN's latest product, intended for use in cardiac surgery and other surgical applications, and it has features such as remote surgery - MN claims that the launch of this product marks India as a "global center for surgical robots". SSI stated that Merai Newage imported an entire surgical robot system called KANGDUO 2000 from China, repackaged it, and launched it without any local manufacturing or value addition, which seriously deviates from the official intention of India to strengthen self-reliance in the medical equipment sector. SSI also questioned the regulatory authorities for issuing a production license for the Mizzo Endo 4000, pointing out that the manufacturer has no production facilities within India. MN insists that although its product components are globally sourced, the safety architecture, core assembly, software integration, and quality inspection are all conducted locally in India. It is worth noting that similar complaints in the Indian medical device industry are not uncommon, but rarely have any follow-up, because according to India's current Drug and Cosmetic Act, even labeling or repackaging is considered manufacturing.
Original: www.toutiao.com/article/1844440051731463/
Statement: This article represents the views of the author(s) alone.